Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Blau Farmaceutica's share price for the quarter that ended in Mar. 2026 was R$10.26. Blau Farmaceutica's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 231 Mil. Therefore, Blau Farmaceutica's market cap for the quarter that ended in Mar. 2026 was R$2,370 Mil.
Blau Farmaceutica's quarterly market cap
increased
from Sep. 2025 (R$2,470 Mil) to Dec. 2025 (R$3,245 Mil) but then
declined
from Dec. 2025 (R$3,245 Mil) to Mar. 2026 (R$2,370 Mil).
Blau Farmaceutica's annual market cap
declined
from Dec. 2023 (R$2,916 Mil) to Dec. 2024 (R$2,337 Mil) but then
increased
from Dec. 2024 (R$2,337 Mil) to Dec. 2025 (R$3,245 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Blau Farmaceutica's Enterprise Value for Today is R$2,074 Mil.
Blau Farmaceutica (BSP:BLAU3) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Blau Farmaceutica Market Cap Related Terms
Blau Farmaceutica Market Cap Historical Data
* Premium members only.
The historical data trend for Blau Farmaceutica's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:BLAU3 vs ZTS, UTHR, VTRS: Market Cap Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Blau Farmaceutica's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Blau Farmaceutica Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Blau Farmaceutica's Market Cap distribution charts can be found below:
* The bar in red indicates where Blau Farmaceutica's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Blau Farmaceutica's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Blau Farmaceutica (BSP:BLAU3) has a Market Cap of R$2,074 Mil as of Jul. 24, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Blau Farmaceutica and its competitors. According to the industry distribution chart, Blau Farmaceutica ranks #419 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 41%.
Is Blau Farmaceutica's Market Cap too high?
Blau Farmaceutica's current Market Cap is R$2,074 Mil. Based on the distribution chart, Blau Farmaceutica ranks #419 out of 1023 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Blau Farmaceutica has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Blau Farmaceutica's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Blau Farmaceutica ranks #419 out of 1023 companies for Market Cap. This puts Blau Farmaceutica in the upper half of its industry. The industry median Market Cap is 213.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 213.63, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Blau Farmaceutica and its competitors. For the Drug Manufacturers industry, the median Market Cap is 213.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Blau Farmaceutica's current Market Cap is R$2,074 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Blau Farmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Blau Farmaceutica (BSP:BLAU3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$11.17, compared to a current price of R$8.98 — trading 19.6% below its estimated fair value. The current Market Cap is R$2,074 Mil. Blau Farmaceutica's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Blau Farmaceutica (BSP:BLAU3), the current Market Cap is R$2,074 Mil as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Blau Farmaceutica (BSP:BLAU3) Overvalued in 2026?
Based on GuruFocus' analysis, Blau Farmaceutica stock appears to be undervalued.
The current stock price of R$8.98 is trading 19.6% below its estimated GF Value™ of R$11.17.
GuruFocus considers Blau Farmaceutica to be Modestly Undervalued.
Key valuation signals for BSP:BLAU3:
Market Cap: R$2,074 Mil
GF Value™: R$11.17 vs. price of R$8.98 (19.6% below fair value)
No single metric tells the full story. See the BSP:BLAU3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Blau Farmaceutica SA is engaged in the manufacturing, development and commercialization of complex private-label drugs for the institutional segment. The Company's business activities cover institutional and retail segments, and are divided into four units: 1) Biologicals are a heterogeneous class of products that can be produced using raw materials from biological materials and biotechnological procedures. 2) Oncology line is made up of oral and injectable drugs intended for treating cancer, which encompasses a number of therapeutic classes. 3) Specialties line is made up of products that are used in the hospital's daily routine, in the specialized treatments for infectious diseases and special treatments. 4) Others consist of prescription and non-prescription over-the-counter drugs.
87GF Score
Get the complete analysis for BSP:BLAU3
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:BLAU3 has been successfully added to your 
